NT-proBNP >200 pg/mL identified severe systolic dysfunction in Duchenne muscular dystrophy with 90.5% sensitivity and 90.9% specificity (AUC 0.96; 95% CI 0.88-1.00).
Cohort
Does NT-proBNP measurement identify severe systolic dysfunction and predict mortality in male patients with Duchenne muscular dystrophy and established cardiomyopathy?
NT-proBNP >200 pg/mL accurately discriminates severe systolic dysfunction in Duchenne muscular dystrophy patients and is associated with mortality, suggesting its utility as a complementary diagnostic biomarker.
Estimación del efecto: AUC 0.96 (95% CI 0.88-1.00)
Background: Cardiomyopathy is a major cause of morbidity and mortality in Duchenne muscular dystrophy (DMD). We evaluated whether N-terminal pro–brain natriuretic peptide (NT-proBNP) identifies severe systolic dysfunction and assessed its diagnostic performance. Methods: Male patients with genetically confirmed DMD and established cardiomyopathy were included if NT-proBNP measurement and echocardiographic ejection fraction (EF) were available within one month. Severe systolic dysfunction was defined as EF 200 pg/mL identified severe systolic dysfunction with 90.5% sensitivity and 90.9% specificity (AUC 0.96, 95% CI 0.88–1.00). During 24 months of follow-up, five deaths occurred. NT-proBNP showed moderate discrimination for mortality (AUC 0.79) and was associated with mortality in exploratory analysis. Conclusions: NT-proBNP was associated with severe systolic dysfunction in Duchenne cardiomyopathy and may complement imaging. Prospective validation is warranted.
Marcì et al. (Mon,) conducted a cohort in Duchenne muscular dystrophy with cardiomyopathy. NT-proBNP was evaluated on Severe systolic dysfunction (EF < 40%) (AUC 0.96, 95% CI 0.88-1.00). NT-proBNP >200 pg/mL identified severe systolic dysfunction in Duchenne muscular dystrophy with 90.5% sensitivity and 90.9% specificity (AUC 0.96; 95% CI 0.88-1.00).